Streetbeat News

Price Targets

RARE

RBC Capital has reiterated its Outperform rating for Ultragenyx Pharmaceutical, maintaining a price target of $77.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2024 | 2:13 pm

AMGN

RBC Capital analyst Gregory Renza has reiterated an 'Outperform' rating for Amgen (NASDAQ:AMGN) and maintained a price target of $362.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2024 | 2:11 pm

ARWR

RBC Capital analyst Luca Issi has reiterated an 'Outperform' rating for Arrowhead Pharma, maintaining a price target of $42.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2024 | 2:09 pm

GEHC

UBS analyst Graham Doyle has downgraded GE HealthCare Techs from Neutral to Sell and reduced the price target from $84 to $74.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2024 | 2:08 pm

AVTR

RBC Capital analyst Conor McNamara has reiterated an Outperform rating on Avantor (NYSE:AVTR) and maintained a price target of $34.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2024 | 2:06 pm

SMAR

UBS analyst Taylor McGinnis has downgraded Smartsheet from Buy to Neutral and reduced the price target from $61 to $56.5.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2024 | 2:05 pm

IMRN

Litchfield Hills has initiated coverage on Immuron (NASDAQ:IMRN) with a Buy rating and set a price target of $5.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2024 | 2:02 pm

CHRW

Analysts have recently updated their ratings and price targets for C.H. Robinson Worldwide (NASDAQ:CHRW). Over the past three months, 13 analysts have shared their insights, with a mix of bullish, neutral, and bearish sentiments. The average 12-month price target has increased by 16.09% to $98.85. Analysts have raised their price targets, reflecting a positive outlook on the company's performance. C.H. Robinson Worldwide is a leading logistics provider with strong financial metrics, including a net margin of 2.82% and a return on equity of 8.59%.

Portfolio Pulse from Benzinga Insights

September 26, 2024 | 2:01 pm

FLUT

Oppenheimer analyst Jed Kelly has maintained an 'Outperform' rating on Flutter Entertainment and raised the price target from $255 to $300.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2024 | 2:00 pm